F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 19.73 USD 1.18% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fortrea Holdings Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Accounts Payable
$132.9m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Accounts Payable
$2.6B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accounts Payable
$1.6B
CAGR 3-Years
-9%
CAGR 5-Years
0%
CAGR 10-Years
-1%
Mettler-Toledo International Inc
NYSE:MTD
Accounts Payable
$202.9m
CAGR 3-Years
-3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Accounts Payable
$497m
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
2%
IQVIA Holdings Inc
NYSE:IQV
Accounts Payable
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
15%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.8B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.

FTRE Intrinsic Value
31.53 USD
Undervaluation 37%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Accounts Payable?
Accounts Payable
132.9m USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Accounts Payable amounts to 132.9m USD.

What is Fortrea Holdings Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
26%

Over the last year, the Accounts Payable growth was 63%. The average annual Accounts Payable growth rates for Fortrea Holdings Inc have been 26% over the past three years .

Back to Top